Sunshine Biopharma Inc.OTCPK - Current
Dec. 28, 2015, 3:20 PM
- Sunshine Biopharma (OTCQB:SBFM +193.1%) purchases the remaining global patents covering lead product candidate, Adva-27a, for $12,822,499. Previously, it held only the U.S. patent.
- Adva-27a inhibits an enzyme called Topoisomerase II, which plays a key role in the cell cycle. Initial targets include pancreatic, breast, uterine and non-small cell lung cancer.